Cognitive Performance and miRNA in Treatment-Naïve and DMT-Treated PWMS
In a study involving 30 treatment-naïve pwRRMS, 30 pwRRMS on DMT, and 30 healthy controls, it was found that miR-21-5p was elevated in treatment-naïve patients, while miR-195-5p was downregulated in all pwRRMS. Additionally, cognitive impairment in DMT-treated pwRRMS correlated with higher MRI lesion burdens.
- Tags
- #MSResearch
- Most relevant to
- —
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- Not graded
- Outcome
- Not reported
Why it matters
The findings highlight potential biomarkers (miRNA and clusterin) linked to MS pathology and cognitive performance, which could guide further research.
What this does not prove
Cognitive impairment was not significantly correlated with miRNA or clusterin levels, and MRI lesion burden showed a stronger association with cognitive status. Larger studies are needed for validation.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- RRMS
- Publication date
- 2026-10-21
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- miR-21-5p, miR-195-5p, clusterin
- Pathway
- Not reported
- Population
- treatment-naïve and DMT-treated pwRRMS
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Cognitive impairment associated with higher lesion burdens.
- Biomarkers
- clusterin
- Safety
- Not reported
Original sources
- Primary evidencePlasma miR-21-5p, miR-195-5p, and clusterin profiles in relapsing-remitting multiple sclerosis and their relationship with cognitive function. ↗DOI: 10.1016/j.neuroscience.2026.10.014
Supporting passages (14)
sample size basis30 treatment-naïve pwRRMS, 30 pwRRMS on disease-modifying therapy (DMT), and 30 healthy controls
relevant ms typesRRMS
publication date2026-10-21
findingsmiR-21-5p expression was significantly elevated in treatment-naïve pwRRMS, while miR-195-5p was downregulated across all pwRRMS compared with controls and these differences persisted after adjustment for age and sex.
findingsmiR-21-5p expression was significantly elevated in treatment-naïve pwRRMS, while miR-195-5p was downregulated across all pwRRMS compared with controls and these differences persisted after adjustment for age and sex.
findingsCognitive impairment in the pwRRMS on DMT group was associated with higher lesion burdens.
limitationsNeither the miRNAs nor clusterin significantly correlated with cognitive impairment status or adjusted BICAMS scores.
limitationsIn this cohort, magnetic resonance imaging lesion burden showed a stronger association with cognitive impairment than circulating biomarkers, and these findings warrant validation in larger multi-center studies.
biological targetsIn silico analysis positioned miR-21-5p, miR-195-5p, and clusterin among genes involved in neuroinflammatory pathways, generating cellular-level hypotheses; their circulating levels primarily reflected systemic inflammatory activity.
populationThe study included 30 treatment-naïve pwRRMS, 30 pwRRMS on disease-modifying therapy (DMT), and 30 healthy controls.
mri endpointsCognitive impairment in the pwRRMS on DMT group was associated with higher lesion burdens.
biomarkersclusterin
peer reviewedPublication types: Journal Article
subjectsThe aim of the study was to investigate the relationship between plasma clusterin, miR-21-5p, and miR-195-5p expression and cognitive performance in patients with relapsing-remitting multiple sclerosis (pwRRMS).
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.